Citadel Advisors - DECIPHERA PHARMACEUTICALS IN ownership

DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 124 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.06 and the average weighting 0.1%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of DECIPHERA PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$3,048,018
+14.1%
239,624
+38.6%
0.00%
Q1 2023$2,671,475
-13.5%
172,911
-8.2%
0.00%
Q4 2022$3,088,630
-43.5%
188,446
-36.2%
0.00%
-100.0%
Q3 2022$5,462,000
+31.8%
295,244
-6.3%
0.00%
-50.0%
Q2 2022$4,145,000
+34.1%
315,213
-5.5%
0.00%
Q1 2022$3,091,000
-17.2%
333,444
-12.7%
0.00%
-100.0%
Q4 2021$3,732,000
-1.2%
381,909
+243.4%
0.00%
Q3 2021$3,779,000
-49.4%
111,227
-45.4%
0.00%
-100.0%
Q2 2021$7,464,000
+280.8%
203,861
+366.4%
0.00%
Q1 2021$1,960,000
-54.6%
43,705
-42.3%
0.00%
Q4 2020$4,319,000
-59.9%
75,687
-63.9%
0.00%
-100.0%
Q3 2020$10,758,000
+274.6%
209,701
+336.1%
0.00%
+100.0%
Q2 2020$2,872,000
-86.3%
48,085
-90.6%
0.00%
-90.0%
Q1 2020$21,032,000
+106.7%
510,877
+212.5%
0.01%
+150.0%
Q4 2019$10,177,000
-26.1%
163,503
-59.7%
0.00%
-33.3%
Q3 2019$13,765,000
+111.2%
405,580
+40.3%
0.01%
+100.0%
Q2 2019$6,517,000
-23.1%
288,997
-20.8%
0.00%
-25.0%
Q1 2019$8,472,000
-24.9%
365,016
-32.1%
0.00%
-33.3%
Q4 2018$11,281,000
-7.6%
537,443
+70.4%
0.01%
+20.0%
Q3 2018$12,215,000
+1030.0%
315,462
+1048.3%
0.01%
+400.0%
Q2 2018$1,081,000
+104.7%
27,471
+4.3%
0.00%
Q1 2018$528,000
-89.4%
26,337
-89.9%
0.00%
-100.0%
Q3 2017$4,965,000261,4360.00%
Other shareholders
DECIPHERA PHARMACEUTICALS IN shareholders Q1 2022
NameSharesValueWeighting ↓
New Leaf Venture Partners, L.L.C. 1,209,571$11,213,0005.53%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 5,580,456$51,731,0001.16%
ARMISTICE CAPITAL, LLC 5,836,000$54,100,0001.05%
Pinz Capital Management, LP 165,835$1,537,0000.96%
Sunesis Advisors, LLC 96,299$893,0000.52%
Redmile Group, LLC 664,817$6,163,0000.19%
PDT Partners, LLC 222,343$2,061,0000.18%
Bayesian Capital Management, LP 41,900$388,0000.06%
Laurion Capital Management LP 459,290$4,258,0000.05%
Hennion & Walsh Asset Management, Inc. 101,643$942,0000.05%
View complete list of DECIPHERA PHARMACEUTICALS IN shareholders